- Home
- IGMS vs NOTE Comparison
IGMS vs NOTE Comparison
Compare IGMS & NOTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IGMS
- NOTE
- Stock Information
- Founded
- IGMS 1993
- NOTE 2013
- Country
- IGMS United States
- NOTE United States
- Employees
- IGMS N/A
- NOTE N/A
- Industry
- IGMS Biotechnology: Pharmaceutical Preparations
- NOTE EDP Services
- Sector
- IGMS Health Care
- NOTE Technology
- Exchange
- IGMS Nasdaq
- NOTE Nasdaq
- Market Cap
- IGMS 82.1M
- NOTE 97.9M
- IPO Year
- IGMS 2019
- NOTE N/A
- Fundamental
- Price
- IGMS $1.26
- NOTE $0.66
- Analyst Decision
- IGMS Hold
- NOTE Strong Buy
- Analyst Count
- IGMS 8
- NOTE 6
- Target Price
- IGMS $6.14
- NOTE $2.63
- AVG Volume (30 Days)
- IGMS 172.4K
- NOTE 1.4M
- Earning Date
- IGMS 05-13-2025
- NOTE 05-12-2025
- Dividend Yield
- IGMS N/A
- NOTE N/A
- EPS Growth
- IGMS N/A
- NOTE N/A
- EPS
- IGMS N/A
- NOTE N/A
- Revenue
- IGMS $2,681,000.00
- NOTE $115,665,000.00
- Revenue This Year
- IGMS $124.45
- NOTE N/A
- Revenue Next Year
- IGMS $45.07
- NOTE $41.32
- P/E Ratio
- IGMS N/A
- NOTE N/A
- Revenue Growth
- IGMS 27.36
- NOTE N/A
- 52 Week Low
- IGMS $0.92
- NOTE $0.56
- 52 Week High
- IGMS $22.50
- NOTE $2.07
- Technical
- Relative Strength Index (RSI)
- IGMS 51.89
- NOTE 50.37
- Support Level
- IGMS $1.13
- NOTE $0.59
- Resistance Level
- IGMS $1.42
- NOTE $0.66
- Average True Range (ATR)
- IGMS 0.09
- NOTE 0.05
- MACD
- IGMS 0.01
- NOTE 0.00
- Stochastic Oscillator
- IGMS 52.94
- NOTE 60.08
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
About NOTE FiscalNote Holdings Inc.
FiscalNote Holdings Inc is a provider of world-wide policy and market intelligence solutions. Leveraging AI and analytics, it delivers actionable legal and policy insights for businesses, government institutions, and nonprofits. Its suite of products includes FiscalNote Core, CQ Federal, and EU Issue Tracker, facilitating effective policy management and risk mitigation. With its analysis from FrontierView, Oxford Analytica, and Dragonfly Eye, it offers geopolitical and market intelligence services. Operating as one segment, it generates revenue by integrating policy intelligence into daily operations. Geographically the company generates the majority of its revenue from North America, Europe, Australia, and Asia, with the majority generated from North America.